Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.00
-33.3%		$0.00
$0.00
▼
$1,903.82
N/A1.3485.48 million shs373,647 shs
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.00
$0.02
$0.00
▼
$0.15
N/AN/A6,269 shs1,199 shs
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
▼
$0.00
N/A-1.52729 shs1,841 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.03
$0.03
$0.02
▼
$0.15
N/AN/A9,337 shs5 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
-33.33%-42.86%-90.24%-84.62%-100.00%
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00%-73.08%-89.63%-95.33%-98.56%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-66.67%0.00%-66.67%-66.67%-50.00%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
+0.00%+2.77%-19.75%-15.03%-48.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.00
-33.3%		$0.00
$0.00
▼
$1,903.82
N/A1.3485.48 million shs373,647 shs
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.00
$0.02
$0.00
▼
$0.15
N/AN/A6,269 shs1,199 shs
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
▼
$0.00
N/A-1.52729 shs1,841 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.03
$0.03
$0.02
▼
$0.15
N/AN/A9,337 shs5 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
-33.33%-42.86%-90.24%-84.62%-100.00%
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00%-73.08%-89.63%-95.33%-98.56%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-66.67%0.00%-66.67%-66.67%-50.00%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
+0.00%+2.77%-19.75%-15.03%-48.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aditxt, Inc. stock logo
ADTX
Aditxt
1.00
SellN/AN/A
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00
N/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aditxt, Inc. stock logo
ADTX
Aditxt
$14.34K0.02N/AN/A$259.70 per share0.00
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$46.18MN/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$1.11MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aditxt, Inc. stock logo
ADTX
Aditxt
-$41.71M-$100,788.35N/AN/AN/A-360,152.50%-374.60%-105.93%12/2/2026 (Estimated)
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A11/18/2026 (Estimated)
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/AN/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest CALA, SXTPW, ADTX, and BFRIW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/18/2026N/A
Biofrontera Inc. stock logo
BFRIW
Biofrontera
-$0.22N/AN/AN/A$8.25 millionN/A
11/17/2026N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$5.5189N/AN/AN/A$0.48 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aditxt, Inc. stock logo
ADTX
Aditxt
N/AN/AN/AN/AN/A
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aditxt, Inc. stock logo
ADTX
Aditxt
N/A
0.06
0.05
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
15.54%
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
0.01%
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aditxt, Inc. stock logo
ADTX
Aditxt
26816,000816,000No Data
Biofrontera Inc. stock logo
BFRIW
Biofrontera
94N/AN/ANot Optionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
603.86 million4.55 millionNot Optionable
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
3N/AN/ANot Optionable

Recent News About These Companies

60 Degrees reports promising babesiosis cure in study
October 27 at 8:31 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-reports-promising-babesiosis-cure-in-study?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Reports Positive Clinical and Molecular Results for Tafenoquine in Expanded Access Babesiosis Study
October 27 at 8:31 AM  |  quiverquant.comQ
60 Degrees highlights interim tafenoquine data, caps enrollment
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-highlights-interim-tafenoquine-data-caps-enrollment?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals to Conclude Enrollment in Severe Babesiosis Trial, Plans January 2027 Unblinding and FDA Meeting
October 6, 2026  |  quiverquant.comQ
60 Degrees Advances Babesiosis Treatment With FDA Submission
September 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-advances-babesiosis-treatment-with-fda-submission?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Reports Second Quarter 2026 Financial Results with 106% Increase in Net Product Revenues
August 14, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-shareholders-approve-key-governance-actions?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-completes-private-placement-to-raise-capital?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Announces $1.0 Million Private Placement of Common Stock and Warrants
July 30, 2026  |  quiverquant.comQ
60 Degrees updates strategy for ARAKODA and profitability
July 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-updates-strategy-for-arakoda-and-profitability?utm_source=marketbeat.com&utm_medium=referral
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study
July 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/interim-trial-plan-finalized-for-tafenoquine-babesiosis-study?utm_source=marketbeat.com&utm_medium=referral
60 Degrees details tafenoquine priority review voucher strategy
June 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-details-tafenoquine-priority-review-voucher-strategy?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals, Inc. Partners with Runway Health to Offer ARAKODA® for Convenient Online Malaria Prevention
April 15, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational Developments
March 31, 2026  |  quiverquant.comQ
60 Degrees Updates Affiliate Share Ownership Disclosure Error
March 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-updates-affiliate-share-ownership-disclosure-error?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering
March 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-updates-legal-opinion-for-atm-offering?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status
February 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-regains-nasdaq-listing-compliance-status?utm_source=marketbeat.com&utm_medium=referral
GoodRx Partners with 60 Degrees Pharmaceuticals to Offer Up to 30% Savings on ARAKODA® for Malaria Prevention
February 2, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting Appeal
January 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-faces-immediate-nasdaq-delisting-appeal?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aditxt stock logo

Aditxt NASDAQ:ADTX

$0.0004 0.00 (-33.33%)
As of 02:58 PM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Biofrontera stock logo

Biofrontera NASDAQ:BFRIW

$0.0014 0.00 (0.00%)
As of 02:22 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0001 0.00 (0.00%)
As of 10/28/2026 11:11 AM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.03 0.00 (0.00%)
As of 10/28/2026

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas